Malaria vaccine: Candidate antigens, mechanisms, constraints and prospects

Scandinavian Journal of Immunology

Volumn 56, Issue 4, 2002, Pages 327-343

  Carvalho, L J M ^a   Daniel Ribeiro, C T ^a   Goto, H ^b  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; DNA VACCINE; MALARIA VACCINE; PROTEIN AMA 1; PROTEIN AS02; PROTEIN CSP; PROTEIN EBA 175; PROTEIN GLURP; PROTEIN HRP2; PROTEIN LSA 3; PROTEIN MSP 1; PROTEIN MSP 2; PROTEIN MSP 3; PROTEIN NANP; PROTEIN NYVAC PF7; PROTEIN RAP 2; PROTEIN RESA; PROTEIN RTS S; PROTEIN SERP; PROTEIN SPF66; PROTEIN TRAP; RAP1 PROTEIN; TOXIN; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DRUG MECHANISM; DRUG RESEARCH; DRUG TARGETING; ERYTHROCYTE; GENOMICS; HUMAN; IMMUNOGENETICS; IN VITRO STUDY; IN VIVO STUDY; LIVER; MALARIA; MEROZOITE; NONHUMAN; PARASITOSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOMICS; REVIEW;

ADULT; ANIMALS; ANOPHELES; ANTIGENS, PROTOZOAN; CEBIDAE; CHILD; DRUG DESIGN; ERYTHROCYTES; FEMALE; FORECASTING; HOST-PARASITE RELATIONS; HUMANS; INSECT VECTORS; LIFE CYCLE STAGES; LIVER; MALARIA; MALARIA VACCINES; MALE; MICE; PLASMODIUM; VACCINES, DNA; VACCINES, SYNTHETIC;

EID: 0036381082     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.2002.01160.x     Document Type: Review

References (136)

1. Breman JG. The ears of the hippopotamus: manifestations, determinants, and estimates of the malaria burden. Am J Trop Med Hyg 2001;64:1-11.
2. Tauil P, Daniel-Ribeiro CT. Some aspects of epidemiology and control of malaria in Brazil. Res Rev Parasitol 1998;58:163-7.
3. Bruce-Chwatt LJ. Essential Malariology. London: William Heinemann Medical Books Ltd., 1985;452.
4. Sergent E, Parrot L. L'immunité, la prémunition et la résistance innée. Arch Inst Pasteur Alger 1935;3:279.
5. Perignon JL, Druilhe P. Immune mechanisms underlying the premunition against Plasmodium falciparum malaria. Mem Inst Oswaldo Cruz 1994;89:51-3.
6. Cohen S, Mcgregor IA. Gamma-globulin and acquired immunity to human malaria. Nature 1961;192:733-7.
7. Bouharoun-Tayoun H, Attanath P, Sabchareon A, Chongsupha-Jarsiddhi T, Druilhe P. Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth in vitro but act in cooperation with monocytes. J Exp Med 1990;172:1633-41.
8. Nussenzweig V, Nussenzweig RS. Rationale for the development of an engineered sporozoite malaria vaccine. Adv Immunol 1989;45:283-334.
9. Baird JK. Host age as a determinant of naturally acquired immunity to Plasmodium falciparum. Parasitol Today 1995;11:105-11.
10. Baird JK, Pornomo Basri H, Bangs MJ et al. Age-specific prevalence of Plasmodium falciparum among six populations with limited histories of exposure to endemic malaria. Am J Trop Med Hyg 1993;49:707-19.
11. Gupta S, Snow RW, Donnelly CA, Marsh K, Newbold C. Immunity to non-cerebral severe malaria is acquired after one or two infections. Nat Med 1999;5:340-3.
12. Kurtis JD, Mtalib R, Onyango Duffy PE. Human resistance to Plasmodium falciparum increases during puberty and is predicted by dehydroepiandrosterone sulfate levels. Infect Immun 2001;69:123-8.
13. Kurtis JD, Hollingdale MR, Luty AJ, Lanar DE, Krzych U, Duffy PE. Pre-erythrocytic immunity to Plasmodium falciparum: the case for an LSA-1 vaccine. Trends Parasitol 2001;17:219-23.
14. Vaz NM, Faria AMC. Guia incompleto de imunobiologia. Belo Horizonte: Coopmed Editora, 1993;242.
15. Ada GL, Ramsay AJ. Vaccines, Vaccination and the Immune Response. Philadelphia: Lippencott-Raven Publishers, 1997;247.
16. Cohen I. Tending Adam's Garden: Evolving the Cognitive Immune System. London: Academic Press, 2000;259.
17. Hoffman SL, Miller LH. Perspectives on malaria vaccine development. In: Hoffman, SL, ed. Malaria Vaccine Development: a Multi-Immune Response Approach. Washington, DC: American Society for Microbiology Press, 1996;35-76.
18. Mercereau-Puijalon O, Fandeur T, Guillotte M, Bonnefoy S. Parasite features impeding malaria immunity: antigenic diversity, antigenic variation and poor immunogenicity. Res Immunol 1991;142:690-7.
19. Craig A, Scherf A. Molecules on the surface of the Plasmodium falciparum infected erythrocyte and their role in malaria pathogenesis and immune evasion. Mol Biochem Parasitol 2001;115:129-43.
20. Good MF, Berzofsky JA, Maloy WL et al. Genetic control of the immune response in mice to a Plasmodium falciparum sporozoite vaccine. Widespread nonresponsiveness to single malaria T epitope in highly repetitive vaccine. J Exp Med 1986;164:655-60.
21. Calvo-Calle JM, Hammer J, Sinigaglia F, Clavijo P, Moya-Castro ZR, Nardin EH. Binding of malaria T cell epitopes to DR and DQ molecules in vitro correlates with immunogenicity in vivo: identification of a universal T cell epitope in the Plasmodium falciparum circumsporozoite protein. J Immunol 1997;159:1362-73.
22. Banic DM, Goldberg AC, Riccio LRP et al. HLA class II control of the immune response to p126-derived aminoterminal peptide from Plasmodium falciparum. Am J Trop Med Hyg (in press).
23. Schuler K, Lu C, Chang HD, Croft M, Zanetti M, Gerloni M. Circumvention of MHC class II restriction by genetic immunization. Vaccine 2001;20:630-4.
24. Banic DM, Viana-Martins FS, De Souza JM, Peixoto TD, Daniel-Ribeiro C. Polyclonal B-lymphocyte stimulation in human malaria and its association with ongoing parasitemia. Am J Trop Med Hyg 1991;44:571-7.
25. Rockett KA, Awburn MM, Rockett EJ, Cowden WB, Clark IA. Possible role of nitric oxide in malarial immunosuppression. Parasite Immunol 1994;16:243-9.
26. Urban BC, Ferguson DJ, Pain A et al. Plasmodium falciparum-infected erythrocytes modulate the maturation of dendritic cells. Nature 1999;400:73-7.
27. Schijns VE. Induction and direction of immune responses by vaccine adjuvants. Crit Rev Immunol 2001;21:75-85.
28. Nat Biotechnol 2000;IT21-3.
29. Nossal GJ. The global alliance for vaccines and immunization - a millennial challenge. Nat Immunol 2000;1:5-8.
30. WHO. Quest for malaria vaccine revs up, but much work remains. Bull WHO 2001;79:1002-3.
31. Ockenhouse CF, Sun PF, Lanar DE et al. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a poxvectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J Infect Dis 1998;177:1664-73.
32. Burghaus PA, Wellde BT, Hall T et al. Immunization of Aotus nancymai with recombinant C terminus of Plasmodium falciparum merozoite surface protein 1 in liposomes and alum adjuvant does not induce protection against a challenge infection. Infect Immun 1996;64:3614-9.
33. Hoffman SL, Franke ED, Hollingdale MR, Druilhe P. Attacking the infected hepatocyte. In: Hoffman, SL, ed. Malaria Vaccine Development: a Multi-Immune Response Approach. Washington, DC: American Society for Microbiology Press, 1996;35-76.
34. Kemp K, Akanmori BD, Adabayeri V et al. Cytokine production and apoptosis from patients under treatment for Plasmodium falciparum malaria. Clin Exp Immunol 2002;127:151-7.
35. Doolan DL, Hoffman SL. The complexity of protective immunity against liver-stage malaria. J Immunol 2000;65:1453-62.
36. WHO/OMS. Memorandum from a WHO meeting: role of nonhuman primates in malaria vaccine development. Bull WHO/OMS 1988;66:719.
37. Stowers AW, Miller LH. Are trials in New World monkeys on the critical path for blood-stage malaria vaccine development? Trends Parasitol 2001;17:415-9.
38. Gray Heppner D, Cummings JF, Ockenhouse C, Kester KE, Lyon JA, Gordon DM. New World monkey efficacy trials for malaria vaccine development: critical path or detour? Trends Parasitol 2001;17:419-25.
39. WHO/TDR. Handbook of Good Laboratory Practice. Geneva, 2001;243.
40. Arévalo-Herrera M, Herrera S. Plasmodium vivax malaria vaccine development. Mol Immunol 2001;38:443-55.
41. Nussenzweig RS, Vanderberg J, Most H, Orton C. Protective immunity produced by the injection of X-irradiated sporozoites of Plasmodium berghei. Nature 1967;216:160-2.
42. Gwadz RW, Cochrane AH, Nussenzweig V, Nussenzweig RS. Preliminary studies on vaccination of rhesus monkeys with irradiated sporozoites of Plasmodium knowlesi and characterization of surface antigens of these parasites. Bull WHO 1979;57:165-73.
43. Clyde DF, McCarthy VC, Miller RM, Woodward WE. Immunization of man against falciparum and vivax malaria by the use of attenuated sporozoites. Am J Trop Med Hyg 1975;24:397-401.
44. Nardin EH, Nussenzweig V, Nussenzweig RS et al. Circumsporozoite proteins of human malaria parasites Plasmodium falciparum and Plasmodium vivax. J Exp Med 1982;156:20-30.
45. Herrington DA, Clyde DF, Losondky G et al. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature 1987;328:257-9.
46. Ballou WR, Hoffman SL, Sherwood JA et al. Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine. Lancet 1987;I:1277-81.
47. Graves P, Gelband H. Vaccines for preventing malaria (Cochrane review). In: The Cochrane Library. Oxford: Update Software, 2002, 1.
48. Stoute JA, Slaoui M, Heppner G et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. N Engl J Med 1997;336:86-91.
49. Doherty JF, Pinder M, Tornieporth N et al. A phase I safety and immunogenicity trial with the candidate malaria vaccine RTS,S/SBAS2 in semi-immune adults in the Gambia. Am J Trop Med Hyg 1999;61:865-8.
50. Bojang KA, Milligan PJ, Pinder M et al. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 2001;358:1927-34.
51. Hill AV, Elvin J, Willis AC et al. Molecular analysis of the association of HLA-B53 and resistance to severe malaria. Nature 1992;360:434-9.
52. Daubersies P, Thomas AW, Millet P et al. Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3. Nat Med 2000;6:1258-63.
53. Mitchell GH, Butcher GA, Cohen S. Merozoite vaccination against Plasmodium knowlesi malaria. Immunology 1975;29:397-407.
54. Chitnis CE. Molecular insights into receptors used by malaria parasites for erythrocyte invasion. Curr Opin Hematol 2001;8:85-91.
55. Chitnis CE, Miller LH. Identification of the erythrocyte binding domains of Plasmodium vivax and Plasmodium knowlesi proteins involved in erythrocyte invasion. J Exp Med 1994;180:497-506.
56. Jakobsen PH, Heegard PM, Koch C et al. Identification of an erythrocyte binding peptide from the erythrocyte binding antigen, EBA-175, which blocks parasite multiplication and induces peptide-blocking antibodies. Infect Immun 1998;66:4203-7.
57. Mitchell GH, Hadley TJ, McGinniss MH, Klotz FW, Miller LH. Invasion of erythrocytes by Plasmodium falciparum malaria parasites: evidence for receptor heterogeneity and two receptors. Blood 1986;67:1519-21.
58. Holder AA. Preventing merozoite invasion of erythrocytes. In: Hoffman, SL, ed. Malaria Vaccine Development: a Multi-Immune Response Approach. Washington, DC: American Society for Microbiology Press, 1996;35-76.
59. Jones TR, Narum DL, Gozalo AS et al. Protection of Aotus monkeys by Plasmodium falciparum EBA-175 region II DNA prime-protein boost immunization regimen. J Infect Dis 2001;183:303-12.
60. Holder AA, Blackman MJ. What is the function of MSP-1 on the malaria merozoite? Parasitol Today 1994;10:182-4.
61. Blackman MJ, Heidrich HG, Donachie S, McBride JS, Holder AA. A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion-inhibiting antibodies. J Exp Med 1990;172:379-82.
62. Holder AA, Freeman RR. Immunization against blood-stage rodent malaria using purified parasite antigens. Nature 1981;294:361-4.
63. Ling IT, Ogun SA, Holder AA. Immunization against malaria with a recombinant protein. Parasite Immunol 1994;16:63-7.
64. Kumar S, Collins W, Egan A et al. Immunogenicity and efficacy in Aotus monkey of four recombinant Plasmodium falciparum vaccines in multiple adjuvant formulations based on the 19-kilodalton C terminal of merozoite surface protein 1. Infect Immun 2000;68:2215-23.
65. Hisaeda H, Saul A, Reece JJ et al. Merozoite surface protein 3 and protection against malaria in Aotus monkeys. J Infect Dis 2002;185:657-64.
66. Keitel WA, Kester KE, Atmar RL et al. Phase I trial of two recombinant vaccines containing the 19 kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1) and T helper epitopes of tetanus toxoid. Vaccine 2000;18:531-9.
67. Epping RJ, Goldstone SD, Ingram LT et al. An epitope recognized by inhibitory monoclonal antibodies that react with a 51 kilodalton merozoite surface antigen in Plasmodium falciparum. Exp Parasitol 1988;81:90-6.
68. Marshall VM, Silva A, Foley M et al. A second merozoite surface protein (MSP-4) of Plasmodium falciparum that contains an epidermal growth factor-like domain. Infect Immun 1997;65:4460-7.
69. Black CG, Wu T, Wang L, Hibbs AR, Coppel RL. Merozoite surface protein 8 of Plasmodium falciparum contains two epidermal growth factor-like domains. Mol Biochem Parasitol 2001;114:217-26.
70. Trucco C, Fernadez-Reyes D, Howell S et al. The merozoite surface protein 6 gene codes for a 36 kDa protein associated with the Plasmodium falciparum merozoite surface protein-1 complex. Mol Biochem Parasitol 2001;112:91-101.
71. Pachebat JA, Ling IT, Grainger M et al. The 22 kDa component of the protein complex on the surface of Plasmodium falciparum merozoites is derived from a larger precursor, merozoite surface protein 7. Mol Biochem Parasitol 2001;117:83-9.
72. Saul A, Lawrence G, Smillie A et al. Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant. Vaccine 1999;17:3145-59.
73. Genton B, Al-Yaman F, Anders R et al. Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea. Vaccine 2000;18:2504-11.
74. Kushwaha A, Rao PP, Suresh RP, Chauban VS. Immunogenicity of recombinant fragments of Plasmodium falciparum acidic basic repeat antigen produced in Escherichia coli. Parasite Immunol 2001;23:435-44.
75. Triglia T, Healer J, Caruana SR et al. Apical membrane antigen 1 plays a central role in erythrocyte invasion by Plasmodium species. Mol Microbiol 2000;38:706-18.
76. Narum DL, Ogun SA, Thomas AW, Holder AA. Immunization with parasite-derived apical membrane antigen 1 or passive immunization with a specific monoclonal antibody protects BALB/c mice against lethal Plasmodium yoelii yoelii YM blood-stage infection. Infect Immun 2000;68:2899-906.
77. Deans JA, Knight AM, Jean WC, Waters AP, Cohen S, Mitchell GH. Vaccination trials in rhesus monkeys with a minor, invariant, Plasmodium knowlesi 66 kD merozoite antigen. Parasite Immunol 1988;10:535-52.
78. Collins WE, Pye D, Crewther PE et al. Protective immunity induced in squirrel monkeys with recombinant apical membrane antigen-1 of Plasmodium fragile. Am J Trop Med Hyg 1994;51:711-9.
79. Collins WE, Walduck A, Sullivan JS et al. Efficacy of vaccines containing rhoptry-associated proteins RAP1 and RAP2 of Plasmodium falciparum in Saimiri boliviensis monkeys. Am J Trop Med Hyg 2000;62:466-79.
80. Tebo AE, Kremsner PG, Luty AJ. Plasmodium falciparum: a major role for IgG3 in antibody-dependent monocyte-mediated cellular inhibition of parasite growth in vitro. Exp Parasitol 2001;98:20-8.
81. Oeuvray C, Bouharoun-Tayoun H, Grass-Masse H et al. Merozoite surface protein-3: a malaria protein inducing antibodies that promote Plasmodium falciparum killing by co-operation with blood monocytes. Blood 1994;84:1594-602.
82. Theisen M, Soe S, Jessing SG et al. Identification of a major B-cell epitope of the Plasmodium falciparum glutamate-rich protein (GLURP), targeted by human antibodies mediating parasite killing. Vaccine 2000;19:204-12.
83. Pouvelle B, Spiegel R, Hsiao L et al. Direct access to serum macromolecules by intraerythrocytic malaria parasites. Nature 1991;353:73-5.
84. Ruangjirachuporn WR, Udomsangpetch R, Carlsson J, Drenckhahn D, Perlmann P, Berzins K. Plasmodium falciparum: analysis of the interaction of antigen Pf155/RESA with the erythrocyte membrane. Exp Parasitol 1991;73:62-72.
85. Chopra N, Biswas S, Thomas B, Sabhnani L, Rao DN. Inducing protective antibodies against ring-infected erythrocyte surface peptide antigen of Plasmodium falciparum using immunostimulating complex (ISCOMs) delivery. Med Microbiol Immunol 2000;189:75-83.
86. Banic DM, Oliveira-Ferreira J, Pratt-Riccio LR et al. Immune response and lack of immune response to Plasmodium falciparum P126 antigen and its amino-terminal repeat in malaria-infected humans. Am J Trop Med Hyg 1998;58:768-74.
87. Lyon JA, Thomas AW, Hall T, Chulay JD. Specificities of antibodies that inhibit merozoite dispersal from malaria-infected erythrocytes. Mol Biochem Parasitol 1989;36:77-85.
88. Borre MB, Dziegiel M, Hogh B et al. Primary structure and localization of a conserved immunogenic Plasmodium falciparum glutamate rich protein (GLURP) expressed in both the preerythrocytic and erythrocytic stages of the vertebrate life cycle. Mol Biochem Parasitol 1991;49:119-32.
89. Dodoo D, Theisen M, Kurtzhals JAL et al. Naturally acquired antibodies to the glutamate-rich protein are associated with protection against Plasmodium falciparum malaria. J Infect Dis 2000;181:1202-5.
90. Leech JH, Barnwell JW, Miller LH, Howard RJ. Identification of a strain-specific malarial antigen exposed on the surface of Plasmodium falciparum-infected erythrocytes. J Exp Med 1984;159:1567-75.
91. Magowan C, Coppel RL, Lau AO, Moronne MM, Tchernia G, Mohandas N. Role of the Plasmodium falciparum mature-parasite-infected erythrocyte surface antigen (MESA/PfEMP-2) in malarial infection of erythrocytes. Blood 1995;86:3196-204.
92. Pasloske BL, Baruch DI, Van Schravendijk MR et al. Cloning and characterization of a Plasmodium falciparum gene encoding a novel high-molecular weight host membrane-associated protein PfEMP3. Mol Biochem Parasitol 1993;59:59-72.
93. Gruner AC, Brahimi K, Eling W et al. The Plasmodium falciparum knob-associated PfEMP3 antigen is also expressed at pre-erythrocytic stages and induces antibodies which inhibit sporozoite invasion. Mol Biochem Parasitol 2001;112:253-61.
94. Schofield L, Hackett F. Signal transduction in host cells by a glycosyphosphatidylinositol toxin of malaria parasites. J Exp Med 1993;177:145-53.
95. Kwiatkowski D, Molyneux ME, Stephens S et al. Anti-TNF therapy inhibits fever in cerebral malaria. Q J Nucl Med 1993;86:91-8.
96. Kwiatkowski D, Hill AV, Sambou I et al. TNF concentration in fatal cerebral, non-fatal cerebral and uncomplicated Plasmodium falciparum malaria. Lancet 1990;336:1201-4.
97. Taverne J, Sheikh N, de Souza JB, Playfair JH, Probert L, Kollias G. Anaemia and resistance to malaria in transgenic mice expressing human tumour necrosis factor. Immunology 1994;82:397-403.
98. Playfair JHL. An anfitoxic vaccine for malaria? In: Hoffman, SL, ed. Malaria Vaccine Development: a Multi-Immune Response Approach. Washington, DC: American Society for Microbiology Press, 1996;35-76.
99. Carter R. Transmission blocking malaria vaccines. Vaccine 2001;19:2309-14.
100. Read D, Lensen AHW, Begarnie S, Haley S, Raza A, Carter R. Transmission-blocking antibodies against multiple target epitopes of the Plasmodium falciparum gamete surface antigen Pfs230 are all complement-fixing. Parasite Immunol 1994;16:511-20.
101. Shahabudin M, Toyoshima T, Aikawa M, Kaslow DC. Transmission-blocking activity of a chitinase inhibitor and activation of malarial parasite chitinase by mosquito protease. Proc Natl Acad Sci USA 1993;90:4266-70.
102. Carter R, Mendis KN, Miller LH, Molineaux L, Saul A. Malaria transmission-blocking vaccines - how can their development be supported? Nat Med 2000;6:241-4.
103. Patarroyo ME, Romero P, Torres ML et al. Induction of protective immunity against experimental infection with malaria using synthetic peptides. Nature 1987;328:629-32.
104. Patarroyo ME, Amador R, Clavijo P et al. A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria. Nature 1988;332:158-61.
105. Urdaneta M, Prata A, Struchiner CJ, Tosta CE, Tauil P, Boulos M. Evaluation of SPf66 malaria vaccine efficacy in Brazil. Am J Trop Med Hyg 1998;58:378-85.
106. D'Alessandro U, Leach A, Drakeley CJ et al. Efficacy trial of malaria vaccine SPf66 in Gambian infants. Lancet 1995;346:462-7.
107. Acosta CJ, Galindo CM, Schellenberg D et al. Evaluation of the SPf66 vaccine for malaria control when delivered through the EPI scheme in Tanzania. Trop Med Int Health 1999;4:368-76.
108. Nosten F, Luxenburger C, Kyke DE et al. Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand. Lancet 1996;348:701-7.
109. Moreno A, Rodriguez R, Oliveira GA et al. Preclinical evaluation of a synthetic Plasmodium falciparum MAP malaria vaccine in Aotus monkeys and in mice. Vaccine 1999;18:89-99.
110. Shi YP, Das P, Holloway B et al. Development, expression, and murine testing of a multistage Plasmodium falciparum malaria vaccine candidate. Vaccine 2000;18:2902-14.
111. Knapp B, Hundt E, Enders B, Kupper HA. Protection of Aotus monkeys from malaria infection by immunization with recombinant hybrid proteins. Infect Immun 1992;60:2397-401.
112. Kocken CH, Hundt E, Knapp B et al. Immunization of Aotus monkeys with recombinant Plasmodium falciparum hybrid proteins does not reproducibly result in protection from malaria infection. Infect Immun 1998;66:373-5.
113. Mascola JR, Nabel GJ. Vaccines for the prevention of HIV-1 disease. Curr Opin Immunol 2001;13:489-95.
114. Mustafa AS. Biotechnology in the development of new vaccines and diagnostic reagents against tuberculosis. Curr Pharm Biotechnol 2001;2:157-73.
115. Gurunathan S, Klinman DM, Seder RA. DNA vaccines: immunology, application, and optimization. Annu Rev Immunol 2000;18:927-74.
116. Krieg AM. Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides. Biochim Biophys Acta 1999;1489:107-16.
117. Lien E, Ingalls RR. Toll-like receptors. Crit Care Med 2002;30:S1-Sll.
118. Nagata T, Uchijima M, Yoshida A, Kawashima M, Koide Y. Codon optimization effect on translational efficiency of DNA vaccine in mammalian cells: analysis of plasmid DNA encoding a CTL epitope derived from microorganisms. Biochem Biophys Res Commun 1999;261:445-51.
119. Narum DL, Kumar S, Rogers WO et al. Codon optimization of gene fragments encoding Plasmodium falciparum merozoite proteins enhances DNA vaccine protein expression and immunogenicity in mice. Infect Immun 2001;69:7250-3.
120. Doolan DL, Hoffman SL. DNA-based vaccines against malaria: status and promise of the Multi-Stage Malaria DNA Vaccine Operation. Int J Parasitol 2001;31:753-62.
121. Sedegah M, Jones TR, Kaur M et al. Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine. Proc Natl Acad Sci USA 1998;95:7648-53.
122. Rogers WO, Baird JK, Kumar A et al. Multistage multiantigen heterologous prime boost vaccine for Plasmodium knowlesi malaria provides partial protection in rhesus macaques. Infect Immun 2001;69:5565-72.
123. Schneider J, Langerman JA, Gilbert SC et al. A prime-boost immunisation regimen using DNA followed by recombinant modified vaccinia virus Ankara induces strong cellular immune responses against the Plasmodium falciparum TRAP antigen in chimpanzees. Vaccine 2001;19:4595-602.
124. Davenport MP, Hill AV. Reverse immunogenetics: from HLA-disease associations to vaccine candidates. Mol Med Today 1996;2:38-45.
125. Lalvani A, Aidoo M, Allsopp CE, Plebanski M, Whittle HC, Hill AV. An HLA-based approach to the design of a CTL-inducing vaccine against Plasmodium falciparum. Res Immunol 1994;145:461-8.
126. Dhiman N, Bonilla R, O'Kane DJ, Poland GA. Gene expression microarrays: a 21st century tool for directed vaccine design. Vaccine 2001;20:22-30.
127. Rappuoli R. Reverse vaccinology, a genome-based approach to vaccine development. Vaccine 2001;19:2688-91.
128. Carucci DJ. Genomic tools for gene and protein discovery in malaria: toward new vaccines. Vaccine 2001;19:2315-8.
129. Hayward RE, Derisi JL, Alfadhli S, Kaslow DC, Brown PO, Rathod PK. Shotgun DNA microarrays and stage-specific gene expression in Plasmodium falciparum malaria. Mol Microbiol 2000;35:6-14.
130. Hoffman SL, Rogers WO, Carucci DJ, Venter JC. From genomics to vaccines: malaria as a model system. Nat Med 1998;4:1351-3.
131. Hoffman SL. Infectious disease. Research (genomics) is crucial to attacking malaria. Science 2000;290:1509.
132. Hoffman SL, Mani Subramanian G, Collins FH, Venter CV. Plasmodium, human and Anopheles genomics and malaria. Nature 2002;415:702-9.
133. Jomaa H, Wiesner J, Sanderbrand S et al. Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs. Science 1999;285:1573-6.
134. Link AJ, Eng J, Schieltz DM et al. Direct analysis of protein complexes using mass spectrometry. Nat Biotechnol 1999;17:676-82.
135. Carucci DJ. Malaria research in the post-genomic era. Parasitol Today 2000;16:434-8.
136. Horrocks P, Bowman S, Kyes S, Waters AP, Craig A. Entering the post-genomic era of malaria research. Bull WHO 2000;78:1424-37.